Infinity Pharmaceuticals Financial Ratios

Infinity Pharmaceuticals Inc -- USA Stock  

USD 1.7  0.12  6.59%

We strongly advise you to harness analysis of Infinity Pharmaceuticals fundamentals to see if markets are presently mispricing the organization. We found thirty-five available reported financial drivers for Infinity Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Shares Owned by Institutions, Net Income, Short Ratio, as well as the relationship between Price to Sales and Debt to Equity . Please also validate Infinity Pharmaceuticals Price to Earning to confirm the company can sustain itself down the road.Use Infinity Pharmaceuticals to protect against small markets fluctuations. The stock experiences very speculative upward sentiment.. Check odds of Infinity Pharmaceuticals to be traded at $1.615 in 30 days

Infinity Pharmaceuticals Valuation Over Time

Enterprise Value

Infinity Pharmaceuticals Company Summary

Infinity Pharmaceuticals competes with NantKwest, Del Mar, VBI Vaccines, and Vascular Biogenics. Its lead product candidate includes IPI145 an oral inhibitor of the delta and gamma isoforms of phosphoinositide3kinase for the treatment of hematologic malignancies. Infinity Pharmaceuticals Inc is developing DYNAMO which is in Phase II study to evaluate the safety and efficacy of IPI145 dosed at 25 mg CONTEMPO that is in the Phase IbII study of IPI145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma BRAVURA which is in Phase III study to evaluate the safety and efficacy of IPI145 plus rituximab and bendamustine and FRESCO that is in Phase II study to evaluate the safety and efficacy of IPI145 plus rituximab. It is also developing DYNAMOR which is in Phase III randomized study to evaluate IPI145 dosed at 25 mg in combination with rituximab a monoclonal antibody treatment DUO that is in randomized Phase III monotherapy study evaluating IPI145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia and SYNCHRONY which is in the Phase Ib study of IPI145 in combination with obinutuzumab in CLL patients. In addition Infinity Pharmaceuticals Inc is conducting a Phase IbII trial of IPI145 in combination with venetoclax a Bcell lymphoma 2 inhibitor and developing IPI549 that is in Phase I study for patients with various solid tumors including melanoma and nonsmall cell lung cancer. Infinity Pharmaceuticals Inc has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI145 in oncology and development and license agreement with Intellikine Inc. to discover develop and commercialize pharmaceutical solutions targeting the delta andor gamma isoforms of PI3K. Infinity Pharmaceuticals Inc. is headquartered in Cambridge Massachusetts.

Infinity Pharmaceuticals Short Ratio vs Cash Flow from Operations

Infinity Pharmaceuticals Inc is rated second overall in short ratio category among related companies. It is rated fourth overall in cash flow from operations category among related companies .

Infinity Pharmaceuticals Systematic Risk

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Infinity Pharmaceuticals correlated with the market. If Beta is less then 0 Infinity Pharmaceuticals generally moves in the opposite direction as compared to the market. If Infinity Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Infinity Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Infinity Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Infinity Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 16% 

Chance of Financial Distress

Infinity Pharmaceuticals Inc has less than 16 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Infinity Pharmaceuticals Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare Infinity Pharmaceuticals To Peers
Adelene Perkins Chairman of The Board, CEO and Pres, MBA
Joseph Pearlberg Vice President - Clinical Development, Ph.D
More Executives

Opportunity Range

December 13, 2017 Opportunity Range